SHH Healthcare Biotechnology 688266.SS

Suzhou Zelgen Biopharmaceuticals Co., Ltd.

$ 89.69 3.09 %

Suzhou Zelgen Biopharmaceuticals Co., Ltd. is a Chinese company engaged in the entire lifecycle of pharmaceutical products, from research and development to manufacturing and sales, within the People's Republic of China. Their product portfolio encompasses both small molecule and recombinant protein-based drugs, which are developed to treat a variety of serious health conditions. These include several types of cancer such as liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, and nasopharyngeal carcinomas. Furthermore, the company's medications address myelofibrosis, hemorrhage, and various hepatobiliary diseases. The firm was established in 2009 and is headquartered in Kunshan, located within the People's Republic of China.

CEO: Zelin Sheng - https://www.zelgen.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ -411.95

Loading data...

688266.SS vs S&P500

Loading data...

No data available.

Quick ratio

2.23

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

47.71

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

1.88

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

39.08 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

15.00 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

5.12

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.61

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

2.55

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

3.77 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
7 indicates good financial health
Altman score
8.03 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
1.66 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.28 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.